About the Authors

Gina Ogilvie

gina.ogilvie@bccdc.ca

Affiliation University of British Columbia, Vancouver, Canada

Maureen Anderson

Affiliation BC Centre for Disease Control, Vancouver, Canada

Fawziah Marra

Affiliation University of British Columbia, Vancouver, Canada

Shelly McNeil

Affiliation Dalhousie University, Halifax, Canada

Karen Pielak

Affiliation BC Centre for Disease Control, Vancouver, Canada

Meena Dawar

Affiliation University of British Columbia, Vancouver, Canada

Marilyn McIvor

Affiliation BC Centre for Disease Control, Vancouver, Canada

Thomas Ehlen

Affiliation University of British Columbia, Vancouver, Canada

Simon Dobson

Affiliation University of British Columbia, Vancouver, Canada

Deborah Money

Affiliation University of British Columbia, Vancouver, Canada

David M. Patrick

Affiliation University of British Columbia, Vancouver, Canada

Monika Naus

Affiliation University of British Columbia, Vancouver, Canada

Competing Interests

SM is a member of the Canadian National Advisory Committee on Immunization. SD is presently a member of the British Columbia Immunization Sub-committee which advises the provincial government on practical issues related to the implementation of publicly funded immunization programs. From 2000 to 2008 SD was a member of the National Advisory Committee on Immunization for Canada. In 2008 SD attended an Advisory Board for Merck for a vaccine not yet licensed. This was not the vaccine used in the Provincial HPV vaccine program discussed in this paper. SD was paid an honorarium for my work on this advisory board.

Author Contributions

ICMJE criteria for authorship read and met: GO MA FM SM KP MD MM TE SD DM DMP MN. Agree with the manuscript's results and conclusions: GO MA FM SM KP MD MM TE SD DM DMP MN. Designed the experiments/the study: GO MA FM SM KP SD DMP MN. Analyzed the data: GO MA MD. Collected data/did experiments for the study: GO MA TE. Enrolled patients: GO MA MN. Wrote the first draft of the paper: GO. Contributed to the writing of the paper: GO FM SM KP MM TE SD DM DMP MN. Revision of document for important intellectual content, and approval of final version: MD. Reviewed the final version of the paper: SD.